Italiano Antoine: Laila Belcaid’s Groundbreaking Study in Precision Oncology at Gustave Roussy
Italiano Antoine, Head of Precision Medicine at Gustave Roussy, shared on LinkedIn:
“Thrilled to see Laila Belcaid – an alumna of my Gustave Roussy team – lead a groundbreaking study featured in the September issue of Annals of Oncology.
In over 2,000 phase I patients, her work spotlights how comprehensive genomic profiling, including RNA‑seq, unearths actionable targets and enables biomarker-matched therapies. This is precision oncology at its best.
Meanwhile, Funda Meric‑Bernstam’s Nature Medicine editorial reminds us just how vital molecular tumor boards (MTBs) are to interpret complex data and translate it into clinical impact.
And here’s where Gustave Roussy’s FRESH program shines: by advancing access to liquid biopsy within precision oncology across France, FRESH strengthens our ability to deliver “on‑time” molecular insights at scale.
Each week, through FRESH, my team reviews ~200 molecular reports to help oncologists tailor therapies and connect patients to relevant clinical trials. This is where data meets patients.
Congratulations, Laila – your work is a beacon for all of us. And thank you to Funda and to every professional who moves precision oncology forward.”
More posts featuring Italiano Antoine.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023